GW&K Investment Management’s Aimmune Therapeutics AIMT Stock Holding History

GW&K Investment Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-295,848	Closed	-$10.2M	–	417
2020 Q3	$10.2M	Sell	295,848 -3,148	-1%	-$67K	0.13%	213
2020 Q2	$5M	Sell	298,996 -4,585	-2%	-$77.8K	0.07%	235
2020 Q1	$4.38M	Buy	303,581 +38,179	+14%	+$976K	0.08%	225
2019 Q4	$8.88M	Sell	265,402 -11,662	-4%	-$326K	0.12%	213
2019 Q3	$5.8M	Buy	277,064 +80,446	+41%	+$1.64M	0.08%	227
2019 Q2	$4.09M	Sell	196,618 -2,074	-1%	-$42.7K	0.06%	256
2019 Q1	$4.44M	Sell	198,692 -30,128	-13%	-$709K	0.07%	224
2018 Q4	$5.47M	Buy	228,820 +42,627	+23%	+$1.1M	0.11%	201
2018 Q3	$5.08M	Buy	+186,193	New	+$5.27M	0.08%	208

GW&K Investment Management's AIMT Position: Q4 2020 in Review

GW&K Investment Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 295,848 shares — an estimated $10.2M sold.

GW&K Investment Management first reported a position in AIMT in Q3 2018 and held it in 9 quarters. The position peaked at $10.2M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

GW&K Investment Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
GW&K Investment Management sold 295,848 Aimmune Therapeutics shares in Q4 2020, an estimated $10.2M.
GW&K Investment Management first reported a position in Aimmune Therapeutics in Q3 2018 and held it in 9 quarters.
GW&K Investment Management's Aimmune Therapeutics position peaked at $10.2M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on GW&K Investment Management's 13F filing for Q4 2020, filed 5 Feb 2021.